Denali Therapeutics Inc. (NASDAQ:DNLI) CEO Sells $7,429,230.00 in Stock

Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) CEO Ryan J. Watts sold 495,282 shares of the stock in a transaction that occurred on Wednesday, July 9th. The stock was sold at an average price of $15.00, for a total value of $7,429,230.00. Following the sale, the chief executive officer owned 253,071 shares in the company, valued at $3,796,065. The trade was a 66.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Denali Therapeutics Trading Down 5.4%

Shares of NASDAQ DNLI traded down $0.83 during mid-day trading on Friday, reaching $14.52. The company had a trading volume of 1,691,789 shares, compared to its average volume of 1,137,148. The stock has a market cap of $2.11 billion, a PE ratio of -5.44 and a beta of 1.33. The company has a 50-day moving average price of $14.29 and a two-hundred day moving average price of $16.64. Denali Therapeutics Inc. has a 1-year low of $10.57 and a 1-year high of $33.33.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.71) by ($0.07). During the same period last year, the business posted ($0.68) earnings per share. On average, research analysts expect that Denali Therapeutics Inc. will post -2.71 EPS for the current year.

Institutional Investors Weigh In On Denali Therapeutics

A number of large investors have recently made changes to their positions in the company. TT International Asset Management LTD acquired a new stake in shares of Denali Therapeutics during the second quarter valued at approximately $909,000. Breakwater Capital Group grew its holdings in shares of Denali Therapeutics by 13.9% during the second quarter. Breakwater Capital Group now owns 17,096 shares of the company's stock valued at $239,000 after buying an additional 2,081 shares in the last quarter. Strs Ohio purchased a new position in shares of Denali Therapeutics during the first quarter valued at $324,000. SCS Capital Management LLC purchased a new position in shares of Denali Therapeutics during the first quarter valued at $2,692,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Denali Therapeutics by 88.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 6,766,916 shares of the company's stock valued at $91,996,000 after buying an additional 3,184,042 shares in the last quarter. Institutional investors and hedge funds own 92.92% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on DNLI. Robert W. Baird dropped their price objective on shares of Denali Therapeutics from $30.00 to $29.00 and set an "outperform" rating on the stock in a report on Thursday, May 8th. Cantor Fitzgerald raised shares of Denali Therapeutics from a "neutral" rating to an "overweight" rating in a research note on Thursday, April 10th. Bank of America lowered their target price on shares of Denali Therapeutics from $28.00 to $27.00 and set a "buy" rating on the stock in a research note on Monday, May 19th. William Blair raised shares of Denali Therapeutics to a "strong-buy" rating in a research note on Thursday, April 24th. Finally, HC Wainwright lowered their target price on shares of Denali Therapeutics from $80.00 to $32.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. One analyst has rated the stock with a hold rating, fourteen have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $33.71.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.